Us Bancorp \De\ Mirati Therapeutics, Inc. Transaction History

Us Bancorp \De\

$71.8 Billion
Q1 2024

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$41.99 - $62.38 $7,474 - $11,103	178 Added 5.29%	3,545 $208,000
Q3 2023 Nov 03, 2023	BUY	$27.8 - $45.35 $63,161 - $103,035	2,272 Added 207.49%	3,367 $146,000
Q2 2023 Aug 09, 2023	SELL	$36.13 - $49.49 $63,588 - $87,102	-1,760 Reduced 61.65%	1,095 $39,000
Q1 2023 May 09, 2023	BUY	$36.54 - $54.26 $37,051 - $55,019	1,014 Added 55.08%	2,855 $106,000
Q4 2022 Feb 13, 2023	SELL	$41.27 - $98.62 $86,543 - $206,806	-2,097 Reduced 53.25%	1,841 $83,000

Q3 2022 Oct 27, 2022	BUY	$59.5 - $86.7 $33,855 - $49,332	569 Added 16.89%	3,938 $275,000
Q2 2022 Aug 01, 2022	BUY	$39.16 - $88.71 $57,604 - $130,492	1,471 Added 77.5%	3,369 $227,000
Q1 2022 May 11, 2022	BUY	$75.82 - $150.97 $112,061 - $223,133	1,478 Added 351.9%	1,898 $156,000
Q4 2021 Feb 11, 2022	SELL	$132.01 - $190.29 $8,976 - $12,939	-68 Reduced 13.93%	420 $63,000
Q3 2021 Nov 10, 2021	BUY	$132.13 - $177.45 $28,540 - $38,329	216 Added 79.41%	488 $86,000
Q2 2021 Aug 05, 2021	BUY	$144.0 - $179.73 $16,560 - $20,668	115 Added 73.25%	272 $44,000
Q1 2021 Apr 28, 2021	BUY	$158.92 - $221.61 $11,442 - $15,955	72 Added 84.71%	157 $27,000
Q4 2020 Feb 04, 2021	BUY	$162.05 - $240.27 $11,667 - $17,299	72 Added 553.85%	85 $19,000
Q3 2020 Nov 10, 2020	BUY	$113.26 - $167.27 $1,472 - $2,174	13 New	13 $2,000
Q1 2020 May 13, 2020	SELL	$69.78 - $116.21 $3,070 - $5,113	-44 Closed	0 $0
Q4 2019 Feb 04, 2020	SELL	$70.76 - $128.86 $566 - $1,030	-8 Reduced 15.38%	44 $6,000
Q3 2019 Nov 08, 2019	SELL	$77.91 - $109.6 $13,400 - $18,851	-172 Reduced 76.79%	52 $4,000
Q2 2019 Aug 13, 2019	BUY	$59.49 - $104.71 $3,688 - $6,492	62 Added 38.27%	224 $23,000
Q1 2019 May 08, 2019	BUY	$43.65 - $78.95 $7,071 - $12,789	162 New	162 $12,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account